Literature DB >> 16830384

Expression of angiopoietins, Tie2 and vascular endothelial growth factor in angiogenesis and progression of hepatocellular carcinoma.

Zhong-Lin Zhang1, Zhi-Su Liu, Quan Sun.   

Abstract

AIM: To investigate the significance of angiopoietins, Tie2 and vascular endothelial growth factor (VEGF) expression in the angiogenesis and progress of hepatocellular carcinoma (HCC).
METHODS: Fresh surgically resected specimens of HCC and noncancerous liver (NCL) tissue from 38 patients with HCC were obtained, and expression of angiopoietin-1 (Ang-1), angiopoietin-2 (Ang-2), Tie2, and VEGF messenger RNA (mRNA) was examined by real-time quantitative reverse transcription-polymerase chain reaction (RT-PCR). Expression pattern of each gene in HCC and NCL tissue specimens was compared and the potential role and interaction in angiogenesis of HCC were analyzed. Genes' expression level and its relationship with tumor's clinicopathological parameters were also investigated. Immunohistochemical staining of CD34 was performed to determine the microvessel density (MVD) and Ang-2/Ang-1 ratio was calculated. Relationships between Ang-2/Ang-1 ratio, VEGF and MVD and clinicopathological features were also tested so as to evaluate their significance in the progression of HCC.
RESULTS: Ang-2 and VEGF mRNAs in HCC were significantly higher than those in NCL tissue (P < 0.05), whereas the Ang-1 and Tie2 mRNAs showed no statistical significance (P > 0.05), though slightly lower level of Ang-1 mRNA in HCC was observed. Ang-2/Ang-1 ratio and VEGF were both positively correlated to MVD. The Ang-2/ Ang-1 ratio, Ang-2 and VEGF were all associated with tumor's clinicopathological parameters (P < 0.05) except for histological grades (P > 0.05). Ang-1 and Tie2 levels in different clinicopathological groups were not significantly different (P > 0.05).
CONCLUSION: Dominant Ang-2 expression against Ang-1 through Tie2 receptor in the presence of VEGF plays a critical role in initiating early neovascularization and transformation of noncancerous liver to hepatocellular carcinoma. Its consequently constant operation in formed HCC induces further angiogenesis and progression of HCC.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16830384      PMCID: PMC4087383          DOI: 10.3748/wjg.v12.i26.4241

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  32 in total

Review 1.  Vasculogenesis and angiogenesis.

Authors:  Sybill Patan
Journal:  Cancer Treat Res       Date:  2004

2.  Microtumor growth initiates angiogenic sprouting with simultaneous expression of VEGF, VEGF receptor-2, and angiopoietin-2.

Authors:  Peter Vajkoczy; Mohammad Farhadi; Andreas Gaumann; Regina Heidenreich; Ralf Erber; Andreas Wunder; Jörg C Tonn; Michael D Menger; Georg Breier
Journal:  J Clin Invest       Date:  2002-03       Impact factor: 14.808

3.  Angiopoietin-2 expression in breast cancer correlates with lymph node invasion and short survival.

Authors:  Christian Sfiligoi; Annarita de Luca; Ilaria Cascone; Valentina Sorbello; Luca Fuso; Riccardo Ponzone; Nicoletta Biglia; Enrica Audero; Riccardo Arisio; Federico Bussolino; Piero Sismondi; Michele De Bortoli
Journal:  Int J Cancer       Date:  2003-02-10       Impact factor: 7.396

4.  Expression and localization of vascular endothelial growth factor receptors in human hepatocellular carcinoma and non-HCC tissues.

Authors:  R Yamaguchi; H Yano; Y Nakashima; S Ogasawara; K Higaki; J Akiba; D J Hicklin; M Kojiro
Journal:  Oncol Rep       Date:  2000 Jul-Aug       Impact factor: 3.906

5.  Biological action of angiopoietin-2 in a fibrin matrix model of angiogenesis is associated with activation of Tie2.

Authors:  K Teichert-Kuliszewska; P C Maisonpierre; N Jones; A I Campbell; Z Master; M P Bendeck; K Alitalo; D J Dumont; G D Yancopoulos; D J Stewart
Journal:  Cardiovasc Res       Date:  2001-02-16       Impact factor: 10.787

Review 6.  New model of tumor angiogenesis: dynamic balance between vessel regression and growth mediated by angiopoietins and VEGF.

Authors:  J Holash; S J Wiegand; G D Yancopoulos
Journal:  Oncogene       Date:  1999-09-20       Impact factor: 9.867

Review 7.  Hepatocellular carcinoma: current management and future trends.

Authors:  Brian I Carr
Journal:  Gastroenterology       Date:  2004-11       Impact factor: 22.682

8.  Effects of thalidomide on angiogenesis and tumor growth and metastasis of human hepatocellular carcinoma in nude mice.

Authors:  Zhong-Lin Zhang; Zhi-Su Liu; Quan Sun
Journal:  World J Gastroenterol       Date:  2005-01-14       Impact factor: 5.742

Review 9.  Vascular remodeling and clinical resistance to antiangiogenic cancer therapy.

Authors:  Julia Glade Bender; Erin M Cooney; Jessica J Kandel; Darrell J Yamashiro
Journal:  Drug Resist Updat       Date:  2004 Aug-Oct       Impact factor: 18.500

10.  Correlation of serum basic fibroblast growth factor levels with clinicopathologic features and postoperative recurrence in hepatocellular carcinoma.

Authors:  R T Poon; I O Ng; C Lau; W C Yu; S T Fan; J Wong
Journal:  Am J Surg       Date:  2001-09       Impact factor: 2.565

View more
  20 in total

Review 1.  Evaluation of antiangiogenic efficacy in advanced hepatocellular carcinoma: Biomarkers and functional imaging.

Authors:  Mohamed Bouattour; Audrey Payancé; Johanna Wassermann
Journal:  World J Hepatol       Date:  2015-09-18

2.  Pericyte-derived glial cell line-derived neurotrophic factor increase the expression of claudin-5 in the blood-brain barrier and the blood-nerve barrier.

Authors:  Fumitaka Shimizu; Yasuteru Sano; Kazuyuki Saito; Masa-aki Abe; Toshihiko Maeda; Hiroyo Haruki; Takashi Kanda
Journal:  Neurochem Res       Date:  2011-10-16       Impact factor: 3.996

3.  Novel antiangiogenic therapies against advanced hepatocellular carcinoma (HCC).

Authors:  R A Pazo-Cid; M Lanzuela; G Esquerdo; J L Pérez-Gracia; A Antón; G Amigo; J Martínez Trufero; A L García-Otín; P Martín-Duque
Journal:  Clin Transl Oncol       Date:  2012-07-18       Impact factor: 3.405

4.  The Selective Tie2 Inhibitor Rebastinib Blocks Recruitment and Function of Tie2Hi Macrophages in Breast Cancer and Pancreatic Neuroendocrine Tumors.

Authors:  Allison S Harney; George S Karagiannis; Jeanine Pignatelli; Bryan D Smith; Ece Kadioglu; Scott C Wise; Molly M Hood; Michael D Kaufman; Cynthia B Leary; Wei-Ping Lu; Gada Al-Ani; Xiaoming Chen; David Entenberg; Maja H Oktay; Yarong Wang; Lawrence Chun; Michele De Palma; Joan G Jones; Daniel L Flynn; John S Condeelis
Journal:  Mol Cancer Ther       Date:  2017-08-24       Impact factor: 6.261

5.  Angiogenesis: multiple masks in hepatocellular carcinoma and liver regeneration.

Authors:  Ji-An Chen; Ming Shi; Jin-Qing Li; Chao-Nan Qian
Journal:  Hepatol Int       Date:  2010-07-29       Impact factor: 6.047

6.  Angiogenesis: from chronic liver inflammation to hepatocellular carcinoma.

Authors:  Paloma Sanz-Cameno; María Trapero-Marugán; María Chaparro; Evan Anthony Jones; Ricardo Moreno-Otero
Journal:  J Oncol       Date:  2010-05-27       Impact factor: 4.375

7.  The antiangiogenic effects of tyroservatide on animal models of hepatocellular carcinoma.

Authors:  Ning Zhang; Lu Wang; Ying Liang; Yi-Ming Zhao; Qiong Xue; Wei-Zhong Wu; Hui-Chuan Sun; Jia Fan; Zhao-You Tang
Journal:  J Cancer Res Clin Oncol       Date:  2009-04-28       Impact factor: 4.553

8.  An intravital microscopic study of the hepatic microcirculation in cirrhotic mice models: relationship between fibrosis and angiogenesis.

Authors:  Eline Vanheule; Anja M Geerts; Jacques Van Huysse; Daphné Schelfhout; Marleen Praet; Hans Van Vlierberghe; Martine De Vos; Isabelle Colle
Journal:  Int J Exp Pathol       Date:  2008-12       Impact factor: 1.925

Review 9.  The Role of Cancer-Associated Fibroblasts and Fibrosis in Liver Cancer.

Authors:  Silvia Affo; Le-Xing Yu; Robert F Schwabe
Journal:  Annu Rev Pathol       Date:  2016-12-05       Impact factor: 23.472

10.  Mechanism-related circulating proteins as biomarkers for clinical outcome in patients with unresectable hepatocellular carcinoma receiving sunitinib.

Authors:  Charles S Harmon; Samuel E DePrimo; Eric Raymond; Ann-Lii Cheng; Eveline Boucher; Jean-Yves Douillard; Ho Y Lim; Jun S Kim; Maria José Lechuga; Silvana Lanzalone; Xun Lin; Sandrine Faivre
Journal:  J Transl Med       Date:  2011-07-25       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.